STOCK TITAN

Moderna to Present at Cowen's 43rd Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Moderna, Inc. (NASDAQ:MRNA) will participate in a fireside chat at Cowen's 43rd Annual Health Care Conference on March 6, 2023, at 9:10 a.m. ET. A live webcast will be available in the Investors section of Moderna's website, with a replay accessible for at least 30 days post-event.

Since its inception over a decade ago, Moderna has advanced mRNA therapeutics and vaccines, notably developing effective COVID vaccines. The company has expanded its clinical portfolio across multiple disease areas, underpinned by strategic alliances and robust manufacturing capabilities. Moderna has been recognized as a leading biopharmaceutical employer by Science for eight consecutive years.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6th at 9:10 a.m. ET.

A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.



View source version on accesswire.com:
https://www.accesswire.com/740894/Moderna-to-Present-at-Cowens-43rd-Annual-Health-Care-Conference

FAQ

When will Moderna present at Cowen's 43rd Annual Health Care Conference?

Moderna will present on March 6, 2023, at 9:10 a.m. ET.

How can I watch Moderna's presentation at the Cowen conference?

A live webcast of the presentation will be available in the Investors section of Moderna's website.

What is Moderna's stock symbol?

Moderna's stock symbol is MRNA.

How long will the replay of Moderna's webcast be available?

The replay of Moderna's webcast will be available for at least 30 days after the presentation.

What is the focus of Moderna's recent developments?

Moderna focuses on messenger RNA therapeutics and vaccines across various disease areas, including infectious diseases and immuno-oncology.

Moderna

NASDAQ:MRNA

MRNA Rankings

MRNA Latest News

MRNA Stock Data

12.98B
347.88M
9.52%
69.66%
11.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE